東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Prediction of Cancer Phenotypes Thro...

Zamalloa, Jose Antonio.

FindBook

Google Book

Amazon

博客來

Prediction of Cancer Phenotypes Through Machine Learning Approaches: From Gene Modularity to Deep Neural Networks.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Prediction of Cancer Phenotypes Through Machine Learning Approaches: From Gene Modularity to Deep Neural Networks./
作者:	Zamalloa, Jose Antonio.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2019,
面頁冊數:	94 p.
附註:	Source: Dissertations Abstracts International, Volume: 80-11, Section: B.
Contained By:	Dissertations Abstracts International80-11B.
標題:	Genetics. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13428420
ISBN:	9781392060131

Prediction of Cancer Phenotypes Through Machine Learning Approaches: From Gene Modularity to Deep Neural Networks.
Zamalloa, Jose Antonio.

Prediction of Cancer Phenotypes Through Machine Learning Approaches: From Gene Modularity to Deep Neural Networks. - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 94 p.

Source: Dissertations Abstracts International, Volume: 80-11, Section: B.

Thesis (Ph.D.)--Princeton University, 2019.

This item must not be sold to any third party vendors.

The current genomics data influx is transforming healthcare by enabling precise diagnoses and individualized treatments. This is especially true for cancer, where we have genome sequencing and gene expression data across numerous individuals, along with measurements of drug response across hundreds of cancer cell lines. Computational, statistical and machine learning methods play an essential role in analyzing these data in order to gain medically relevant insights. In this dissertation, I describe statistical and machine learning approaches to enable better stratification of cancer subtypes and predict therapy outcomes for individuals with cancer.First, I introduce Deep Pharmacogenomic Modules (Deep-PGMs), a framework to predict drug response outcomes for tumor samples using drug features and gene expression data. Genome expression signatures are a great aid for predicting whether a particular therapy may be beneficial for a specific cancer tumor. Traditional ma- chine learning approaches to predict the effect of a cancer drug on a tumor typically focus on the expression levels of either certain key cancer-relevant genes or of all genes. While genomic data can aid in describing the disease state of an individual by looking at isolated gene entities, genes in cells tend to act in concert to perform their functions. My approach takes advantage of the modular nature of gene regulation to build a reduced feature space that describes the cellular state of a tumor. I take advantage of unsupervised machine learning methods to build genomic and non-genomic feature spaces. I construct a deep neural network pipeline to predict drug efficacy outcomes on tumor cell line samples. I demonstrate that my framework outperforms traditional machine learning approaches that do not take advantage of the modular structure of gene expression data sets. I further apply my method to clinical trial data and demonstrate its performance. I find that featurizing genomic data through prior knowledge about cellulary modularity, accompanied with a robust deep learning pipeline, is a powerful method for predicting the disease outcome of novel cancer therapeutics.In the second part of my thesis, I develop classifiers to identify two breast cancer subtypes. First, I describe an accurate Claudin-low (CL) molecular subtype predictor based on gene expression data. This particular subtype has poor prognosis in breast cancer patients. Via experiments in mice along with analysis of human breast cancer data, my collaborators and I linked individuals with CL breast cancer to elevated levels of miR-199a. This evidence further supported the high levels of miR-199a in mice tumors and helped characterize the miR-199a-LCOR-IFN axis in tumor initiation. Next, I developed a hysteretic epithelial-mesenchymal transition (EMT) classifier. I use experimental data from TGF-β induced EMT mouse mammary tumor cells to find genes that are indicative of the hysteretic EMT phenotype. The uncovered genes in my model correlate well with metastatic phenotypes in clinical datasets, particularly in patients with metastatic lung cancer, suggesting that EMT-induced mice mammary tumor cells can help elucidate clinically relevant genes important in metastasis.

ISBN: 9781392060131Subjects--Topical Terms:

530508
Genetics.

Prediction of Cancer Phenotypes Through Machine Learning Approaches: From Gene Modularity to Deep Neural Networks.
LDR:04396nmm a2200349 4500 001 2210707
005 20191121124300.5
008 201008s2019 ||||||||||||||||| ||eng d
020 $a 9781392060131
035 $a (MiAaPQ)AAI13428420
035 $a (MiAaPQ)princeton:12877
035 $a AAI13428420
040 $a MiAaPQ $c MiAaPQ
100 1 $a Zamalloa, Jose Antonio. $3 3437842
245 1 0 $a Prediction of Cancer Phenotypes Through Machine Learning Approaches: From Gene Modularity to Deep Neural Networks.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 94 p.
500 $a Source: Dissertations Abstracts International, Volume: 80-11, Section: B.
500 $a Publisher info.: Dissertation/Thesis.
500 $a Advisor: Singh, Mona.
502 $a Thesis (Ph.D.)--Princeton University, 2019.
506 $a This item must not be sold to any third party vendors.
520 $a The current genomics data influx is transforming healthcare by enabling precise diagnoses and individualized treatments. This is especially true for cancer, where we have genome sequencing and gene expression data across numerous individuals, along with measurements of drug response across hundreds of cancer cell lines. Computational, statistical and machine learning methods play an essential role in analyzing these data in order to gain medically relevant insights. In this dissertation, I describe statistical and machine learning approaches to enable better stratification of cancer subtypes and predict therapy outcomes for individuals with cancer.First, I introduce Deep Pharmacogenomic Modules (Deep-PGMs), a framework to predict drug response outcomes for tumor samples using drug features and gene expression data. Genome expression signatures are a great aid for predicting whether a particular therapy may be beneficial for a specific cancer tumor. Traditional ma- chine learning approaches to predict the effect of a cancer drug on a tumor typically focus on the expression levels of either certain key cancer-relevant genes or of all genes. While genomic data can aid in describing the disease state of an individual by looking at isolated gene entities, genes in cells tend to act in concert to perform their functions. My approach takes advantage of the modular nature of gene regulation to build a reduced feature space that describes the cellular state of a tumor. I take advantage of unsupervised machine learning methods to build genomic and non-genomic feature spaces. I construct a deep neural network pipeline to predict drug efficacy outcomes on tumor cell line samples. I demonstrate that my framework outperforms traditional machine learning approaches that do not take advantage of the modular structure of gene expression data sets. I further apply my method to clinical trial data and demonstrate its performance. I find that featurizing genomic data through prior knowledge about cellulary modularity, accompanied with a robust deep learning pipeline, is a powerful method for predicting the disease outcome of novel cancer therapeutics.In the second part of my thesis, I develop classifiers to identify two breast cancer subtypes. First, I describe an accurate Claudin-low (CL) molecular subtype predictor based on gene expression data. This particular subtype has poor prognosis in breast cancer patients. Via experiments in mice along with analysis of human breast cancer data, my collaborators and I linked individuals with CL breast cancer to elevated levels of miR-199a. This evidence further supported the high levels of miR-199a in mice tumors and helped characterize the miR-199a-LCOR-IFN axis in tumor initiation. Next, I developed a hysteretic epithelial-mesenchymal transition (EMT) classifier. I use experimental data from TGF-β induced EMT mouse mammary tumor cells to find genes that are indicative of the hysteretic EMT phenotype. The uncovered genes in my model correlate well with metastatic phenotypes in clinical datasets, particularly in patients with metastatic lung cancer, suggesting that EMT-induced mice mammary tumor cells can help elucidate clinically relevant genes important in metastasis.
590 $a School code: 0181.
650 4 $a Genetics. $3 530508
650 4 $a Bioinformatics. $3 553671
650 4 $a Physiology. $3 518431
650 4 $a Oncology. $3 751006
690 $a 0369
690 $a 0715
690 $a 0719
690 $a 0992
710 2 $a Princeton University. $b Quantitative Computational Biology. $3 2102181
773 0 $t Dissertations Abstracts International $g 80-11B.
790 $a 0181
791 $a Ph.D.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13428420